771 related articles for article (PubMed ID: 18297583)
1. Antipsychotics, glycemic disorders, and life-threatening diabetic events: a Bayesian data-mining analysis of the FDA adverse event reporting system (1968-2004).
DuMouchel W; Fram D; Yang X; Mahmoud RA; Grogg AL; Engelhart L; Ramaswamy K
Ann Clin Psychiatry; 2008; 20(1):21-31. PubMed ID: 18297583
[TBL] [Abstract][Full Text] [Related]
2. Atypical antipsychotic drugs and diabetes mellitus in the US Food and Drug Administration Adverse Event database: a systematic Bayesian signal detection analysis.
Baker RA; Pikalov A; Tran QV; Kremenets T; Arani RB; Doraiswamy PM
Psychopharmacol Bull; 2009; 42(1):11-31. PubMed ID: 19204649
[TBL] [Abstract][Full Text] [Related]
3. Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.
Szarfman A; Tonning JM; Levine JG; Doraiswamy PM
Pharmacotherapy; 2006 Jun; 26(6):748-58. PubMed ID: 16716128
[TBL] [Abstract][Full Text] [Related]
4. Influence of the MedDRA hierarchy on pharmacovigilance data mining results.
Pearson RK; Hauben M; Goldsmith DI; Gould AL; Madigan D; O'Hara DJ; Reisinger SJ; Hochberg AM
Int J Med Inform; 2009 Dec; 78(12):e97-e103. PubMed ID: 19230751
[TBL] [Abstract][Full Text] [Related]
5. Potential for linezolid-related blindness: a review of spontaneous adverse event reports.
Brown J; Aitken SL; van Manen RP
Pharmacotherapy; 2011 Jun; 31(6):585-90. PubMed ID: 21923442
[TBL] [Abstract][Full Text] [Related]
6. An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA's spontaneous adverse event reporting system.
Colman E; Szarfman A; Wyeth J; Mosholder A; Jillapalli D; Levine J; Avigan M
Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1068-76. PubMed ID: 18821724
[TBL] [Abstract][Full Text] [Related]
7. Contrast media and nephropathy: findings from systematic analysis and Food and Drug Administration reports of adverse effects.
Solomon R; Dumouchel W
Invest Radiol; 2006 Aug; 41(8):651-60. PubMed ID: 16829749
[TBL] [Abstract][Full Text] [Related]
8. Reports of hyperkalemia after publication of RALES--a pharmacovigilance study.
Hauben M; Reich L; Gerrits CM
Pharmacoepidemiol Drug Saf; 2006 Nov; 15(11):775-83. PubMed ID: 16804951
[TBL] [Abstract][Full Text] [Related]
9. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.
Roberto G; Piccinni C; D'Alessandro R; Poluzzi E
Cephalalgia; 2014 Jan; 34(1):5-13. PubMed ID: 23921799
[TBL] [Abstract][Full Text] [Related]
10. The influence of study design on the results of pharmacoepidemiologic studies of diabetes risk with antipsychotic therapy.
Gianfrancesco F; Wang RH; Nasrallah HA
Ann Clin Psychiatry; 2006; 18(1):9-17. PubMed ID: 16517448
[TBL] [Abstract][Full Text] [Related]
11. Are all quantitative postmarketing signal detection methods equal? Performance characteristics of logistic regression and Multi-item Gamma Poisson Shrinker.
Berlin C; Blanch C; Lewis DJ; Maladorno DD; Michel C; Petrin M; Sarp S; Close P
Pharmacoepidemiol Drug Saf; 2012 Jun; 21(6):622-30. PubMed ID: 21994119
[TBL] [Abstract][Full Text] [Related]
12. Serious adverse events with infliximab: analysis of spontaneously reported adverse events.
Hansen RA; Gartlehner G; Powell GE; Sandler RS
Clin Gastroenterol Hepatol; 2007 Jun; 5(6):729-35. PubMed ID: 17481964
[TBL] [Abstract][Full Text] [Related]
13. Topical bovine thrombin: a 21-year review of topical bovine thrombin spontaneous case safety reports submitted to FDA's Adverse Event Reporting System.
Clark JA; Humphries JE; Crean S; Reynolds MW
Pharmacoepidemiol Drug Saf; 2010 Feb; 19(2):107-14. PubMed ID: 20014051
[TBL] [Abstract][Full Text] [Related]
14. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
Wysowski DK; Swartz L
Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
[TBL] [Abstract][Full Text] [Related]
15. Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs.
Morrato EH; Druss B; Hartung DM; Valuck RJ; Allen R; Campagna E; Newcomer JW
Arch Gen Psychiatry; 2010 Jan; 67(1):17-24. PubMed ID: 20048219
[TBL] [Abstract][Full Text] [Related]
16. Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.
Gandhi PK; Gentry WM; Bottorff MB
Pharmacotherapy; 2012 Oct; 32(10):902-9. PubMed ID: 23033229
[TBL] [Abstract][Full Text] [Related]
17. Comparing data mining methods on the VAERS database.
Banks D; Woo EJ; Burwen DR; Perucci P; Braun MM; Ball R
Pharmacoepidemiol Drug Saf; 2005 Sep; 14(9):601-9. PubMed ID: 15954077
[TBL] [Abstract][Full Text] [Related]
18. Disproportionality analysis for signal detection of implantable cardioverter-defibrillator-related adverse events in the Food and Drug Administration Medical Device Reporting System.
Duggirala HJ; Herz ND; Caños DA; Sullivan RA; Schaaf R; Pinnow E; Marinac-Dabic D
Pharmacoepidemiol Drug Saf; 2012 Jan; 21(1):87-93. PubMed ID: 22095760
[TBL] [Abstract][Full Text] [Related]
19. Postmarketing hepatic adverse event experience with PEGylated/non-PEGylated drugs: a disproportionality analysis.
Hauben M; Vegni F; Reich L; Younus M
Eur J Gastroenterol Hepatol; 2007 Nov; 19(11):934-41. PubMed ID: 18049161
[TBL] [Abstract][Full Text] [Related]
20. Pediatric drug surveillance and the Food and Drug Administration's adverse event reporting system: an overview of reports, 2003-2007.
Johann-Liang R; Wyeth J; Chen M; Cope JU
Pharmacoepidemiol Drug Saf; 2009 Jan; 18(1):24-7. PubMed ID: 19009550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
